Lisa McGregor, MD, PhD

    • 818 Citations
    • 17 h-Index
    1994 …2020

    Research output per year

    If you made any changes in Pure these will be visible here soon.

    Fingerprint Dive into the research topics where Lisa McGregor is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

    • 2 Similar Profiles

    Network Recent external collaboration on country level. Dive into details by clicking on the dots.

    Research Output

    • 818 Citations
    • 17 h-Index
    • 34 Article
    • 2 Review article
    • 1 Letter

    A phase 1 trial of everolimus and bevacizumab in children with recurrent solid tumors

    Santana, V. M., Sahr, N., Tatevossian, R. G., Jia, S., Campagne, O., Sykes, A., Stewart, C. F., Furman, W. L. & McGregor, L. M., Jan 1 2020, (Accepted/In press) In : Cancer.

    Research output: Contribution to journalArticle

  • Phase i clinical trial of ifosfamide, oxaliplatin, and etoposide (IOE) in pediatric patients with refractory solid tumors

    Lam, C. G., Furman, W. L., Wang, C., Spunt, S. L., Wu, J., Ivy, P., Santana, V. M. & McGregor, L. M., Jan 3 2015, In : Journal of Pediatric Hematology/Oncology. 37, 1, p. e13-e18

    Research output: Contribution to journalArticle

  • 2 Scopus citations

    Subsequent malignant neoplasms in pediatric patients initially diagnosed with neuroblastoma

    Federico, S. M., Allewelt, H. B., Spunt, S. L., Hudson, M. M., Wu, J., Billups, C. A., Jenkins, J., Santana, V. M., Furman, W. L. & McGregor, L. M., Jan 3 2015, In : Journal of Pediatric Hematology/Oncology. 37, 1, p. e6-e12

    Research output: Contribution to journalArticle

  • 11 Scopus citations

    Phase i dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors

    Brennan, R. C., Furman, W., Mao, S., Wu, J., Turner, D. C., Stewart, C. F., Santana, V. & McGregor, L., Dec 2014, In : Cancer Chemotherapy and Pharmacology. 74, 6, p. 1191-1198 8 p.

    Research output: Contribution to journalArticle

  • 11 Scopus citations

    Phase I trial of a novel anti-GD2 monoclonal antibody, hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma

    Navid, F., Sondel, P. M., Barfield, R., Shulkin, B. L., Kaufman, R. A., Allay, J. A., Gan, J., Hutson, P., Seo, S., Kim, K. M., Goldberg, J., Hank, J. A., Billups, C. A., Wu, J., Furman, W. L., McGregor, L. M., Otto, M., Gillies, S. D., Handgretinger, R. & Santana, V. M., May 10 2014, In : Journal of Clinical Oncology. 32, 14, p. 1445-1452 8 p.

    Research output: Contribution to journalArticle

  • 82 Scopus citations